Last update 21 Nov 2024

SHR-A1912

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Target
CD79B
Mechanism
CD79B inhibitors(B-cell antigen receptor complex-associated protein beta chain inhibitors)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication
LymphomaB-Cell Lymphoma
Inactive Indication-
Originator Organization
Shanghai Hengrui Pharmaceutical Co., Ltd.Shanghai Hengrui Pharmaceutical Co., Ltd.
Active Organization
Jiangsu Hengrui Pharmaceuticals Co., Ltd.Jiangsu Hengrui Pharmaceuticals Co., Ltd.Shanghai Hengrui Pharmaceutical Co., Ltd.Shanghai Hengrui Pharmaceutical Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (US)
Login to view timeline

Structure

Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

4
Clinical Trials associated with SHR-A1912
NCT06104553 / RecruitingPhase 1/2
A Phase Ib/II Study of SHR-A1912 Combined With Other Therapies in Patients With B-cell Non-Hodgkin 's Lymphoma
CTR20233679 / RecruitingPhase 1/2
SHR-A1912联合治疗在B细胞非霍奇金淋巴瘤中的IB/II期研究
[Translation] Phase IB/II Study of SHR-A1912 Combination Therapy in B-Cell Non-Hodgkin Lymphoma
NCT05113069 / Enrolling by invitationPhase 1
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1912 for Injection as Monotherapy in Patients With B-cell Lymphoma
100 Clinical Results associated with SHR-A1912
Login to view more data
100 Translational Medicine associated with SHR-A1912
Login to view more data
100 Patents (Medical) associated with SHR-A1912
Login to view more data
100 Deals associated with SHR-A1912
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
B-Cell LymphomaPhase 2
CN
Shanghai Hengrui Pharmaceutical Co., Ltd.Shanghai Hengrui Pharmaceutical Co., Ltd.
17 Nov 2023
LymphomaPhase 2
CN
Jiangsu Hengrui Pharmaceuticals Co., Ltd.Jiangsu Hengrui Pharmaceuticals Co., Ltd.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT05113069 (phase 1 study of SHR-A1912, ASCO2024)
Phase 1
B-Cell Lymphoma
49
(sahidcarat) = xjoduozfgl qhudvomjru (kjkdoqnomx, 39.8 - 71.5)
Positive
24 May 2024
(sahidcarat) = nwfyuogfcw qhudvomjru (kjkdoqnomx, 39.8 - 71.5)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free